Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.

Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation

Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible and easier to administer.

Merck says Keytruda injection on par with approved IV version in trial

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck's anti-PD-1 therapy, available for intravenous use as KEYTRUDA®, together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; “subcutaneous pembrolizumab”).

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.

Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increases in the second half of November, including modest increases from Merck and a 10%+ increase from Raymond James Financial. Hormel Foods is expected to announce its 59th consecutive year of dividend growth, highlighting its long-term commitment to dividend increases.

Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November

CMS Energy

Mondelez

PepsiCo

The October producer price index edged up to 2.4%. Ongoing inflation could temper how many rate cuts are in line for 2025.

Inflation Is Still Here: Grab These 4 High-Yield Dividend Blue Chips to Fight It Now

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Moderna

Pfizer

Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.

As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.

Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy

AstraZeneca

BioNTech SE

Inovio Pharmaceuticals

Sanofi

Valneva SE

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

European And US Vaccine Stocks Are Under Pressure - Here's WHy

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM). “The.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)

Avangrid

American Water Works

Bank of America

Ball Corp

Best Buy

Franklin Resources

Constellation Energy Corp

Campbell Soup

Eversource Energy

Exelon

General Mills

Hasbro

Hormel Foods

Intel

Interpublic Group of Companies

Kraft Heinz

NextEra Energy

Ormat Technologies

Prudential Financial

Regions Financial

Stanley Black & Decker

Texas Instruments

Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sustainable companies offer dividends exceeding their share prices, signalling potential buy opportunities for investors. Analysts estimate net gains of 17.47% to 69.69% for the top ten sustainable companies by November 2025, based on target prices and dividends.

100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys

Summit Therapeutics

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug. The post Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics appeared first on Investor's Business Daily.

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 to 2032. Declining Gardasil sales in China and competition from Summit Therapeutics and Roche's Tecentriq may have contributed to recent stock volatility.

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference.

Merck to Participate in the Jefferies London Healthcare Conference

Roche Holding AG

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. The Global Immunology Biosimilars market showcased growth at a CAGR of 17.92% during 2020-2023. The market was valued at USD 8.03 billion in 2023 which is expected to reach USD 16.22 billion in 2030. This report provides an analysis for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The global Immunology Biosimilars market is expected to witness strong growth during the forecast period, driven by multiple factors. A key factor is the rising incidence of chronic immunological conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, which is fueling the demand for cost-effective treatment solutions. As affordable alternatives to branded biologics, biosimilars are gaining significant traction, especially in regions with well-established healthcare systems and expanding patient populations. Another major growth driver is the expiration of patents on blockbuster biologic drugs, opening the door for biosimilars to enter the market. This trend is particularly evident in developed markets like Europe and the Americas, where governments are promoting the use of biosimilars through favorable regulatory policies aimed at lowering healthcare costs. In addition, the expansion of healthcare infrastructure in emerging markets, notably in the Asia Pacific region, is facilitating wider access to advanced therapies, boosting the demand for immunology biosimilars. Rising awareness of biosimilars and government-led initiatives are also expected to further stimulate market growth. Moreover, leading industry players are increasingly focusing on strategic partnerships and ramping up investments in research and development to enhance their product offerings and expand their market reach, driving the market's continued expansion. Scope of the Report

Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,.

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.

Merck signs $3.3 bln deal for experimental cancer drug

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. “At Merck, we continue to assemble a strong and diversified oncology pipeline spanning differentiated mechanisms an.

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

Merck & Co., Inc. (NYSE:MRK ) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinical Research Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're at time here.

Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs.

KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

If you're patient, these businesses have a lot of promising projects in the works.

2 Hot Biopharma Stocks to Buy and Hold for 5 Years

Dollar General

NIKE

These stocks have seen better days but investors shouldn't count them out in the long run.

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.

Keytruda, Merck's flagship oncology drug, drives significant revenue growth, with a solid market position and patent protection ensuring continued growth. Merck is the second largest player in the oncology drugs industry, which is expected to observe a 6.7% CAGR over the next five years. Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment appeal.

Merck: An Undervalued Dividend Machine

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared to the consensus estimates of $16.5 billion and $1.50, respectively.

Is MRK Stock Undervalued At $100?

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the UBS Global Healthcare Conference.

News for Merck Stock (MRK)